By Tom Zanki for NJBIZ
Johnson & Johnson has a binding offer to sell its Ortho-Clinical Diagnostics business to The Carlyle Group for $4.15 billion, the company announced early Thursday morning.
Alex Gorsky, the chairman and chief executive officer of Johnson & Johnson, said the deal makes sense for the New Brunswick-based company.
"Ortho-Clinical Diagnostics plays an important role in health care, and we're confident that it's well positioned to serve the interests of its patients, customers and employees," he said in a release. "This transaction is a result of our disciplined approach to portfolio management in order to achieve the greatest value for Johnson & Johnson."
The acceptance period for the offer will end on March 31.
Johnson & Johnson said it will consult with relevant works councils and trade unions before finalizing the deal.
The company, which said it would hope to close the deal by the middle of the year, will discuss the deal at its quarterly earnings meeting next Tuesday.
According to the release, Ortho-Clinical Diagnostics produces vitro diagnostic products that give health care professionals around the world the knowledge they need to make better treatment decisions sooner.
The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit. Ortho-Clinical Diagnostics also brings information management, testing technologies and automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care.
Like NJBIZ on Facebook: facebook.com/NJBIZ